CoChat
Sign Up
Cited by 135Cannabis and Cannabinoid ResearchSmoking Behavior and CessationSubstance Abuse Treatment and Outcomes

Bupropion SR worsens mood during marijuana withdrawal in humans

Haney, Margaret, Ward, Amie S., Comer, Sandra D., Hart, Carl L., Foltin, Richard W., Fischman, Marian W.·2001·Psychopharmacology
DOI 10.1007/s002130000657
Open this paper in CoChat — free account

Abstract

Rationale Symptoms of withdrawal after daily marijuana smoking include increased ratings of irritability and depression. Similar mood symptoms are reported by cigarette smokers during nicotine abstinence. Objective Given the successful use of sustained-release bupropion in treating nicotine dependence, this study investigated how maintenance on bupropion influenced symptoms of marijuana withdrawal compared to maintenance on placebo. Methods Marijuana smokers (n=10) were maintained outpatient on active (300 mg/day) or placebo (0 mg/day) bupropion for 11 days, and were then maintained inpatient on the same bupropion dose for 17 days. For the first 4 inpatient days, participants smoked active marijuana [2.8% delta9-tetrahydrocannabinol (THC)] 5 times/day. For the remaining inpatient days, participants smoked placebo marijuana (0.0% THC) 5 times/day. Participants were then maintained outpatient on the alternate dose of bupropion for 11 days, followed by a second inpatient residential stay, paralleling the first. Medication administration was double-blind. Mood, psychomotor task performance, food intake, and sleep were measured daily during each inpatient phase. The order of active and placebo bupropion maintenance was counterbalanced between groups. Results Bupropion had few behavioral effects when participants smoked active marijuana. During placebo marijuana smoking, i.e., active marijuana withdrawal, ratings of irritability, restlessness, depression, and trouble sleeping were…

Integrity signals

Registry

Crossref · 10.1007/s002130000657

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients withdrawing from marijuana, total sleep time and getting to sleep were particularly poor for those taking bupropion in the first 3 days of withdrawal.

    “(Haney et al., 2001) observed that bupropion (300mg) was associated with poorer sleep than placebo in patients withdrawing from marijuana; total sleep time and getting to sleep were particularly poor for those taking bupropion in the first 3 days of withdrawal.”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Haney et al., 2001

  • In patients withdrawing from marijuana, bupropion 300 mg was associated with poorer sleep than placebo.

    “(Haney et al., 2001) observed that bupropion (300mg) was associated with poorer sleep than placebo in patients withdrawing from marijuana; total sleep time and getting to sleep were particularly poor for those taking bupropion in the first 3 days of withdrawal.”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Haney et al., 2001

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Haney, M., Ward, A. S., Comer, S. D., Hart, C. L., Foltin, R. W., & Fischman, M. W.
Affiliations
New York State Psychiatric Institute (US)
ORCID
Venue
Psychopharmacology
Publisher
Springer Science and Business Media LLC
Published
2001-03-30
Volume
155
Issue
2
Pages
171-179
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
DOI
10.1007/s002130000657
OpenAlex
W1970664643
Cited by
135
References
3
Citations by year
2026: 2 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 7 · 2017: 4 · 2016: 5 · 2015: 9 · 2014: 10 · 2013: 6 · 2012: 9
FWCI
3.30
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Drug Abuse (P50DA009236, R01DA003476)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
bupropion, cannabis use disorder, mood, irritability, depression, bupropion sustained release, tobacco dependence treatment, delta-9-tetrahydrocannabinol, sleep disorders, psychomotor performance, dietary intake
MeSH terms
Adult, Affect, Cannabis, Eating, Female, Humans, Male, Psychomotor Performance, Sleep, Smoking, Social Behavior, Substance Withdrawal Syndrome, Bupropion, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review